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ABSTRACT 
 
Emergence of multidrug resistant (MDR) bacteria is a major concern to global 
health. One of the major MDR mechanisms bacteria employ is efflux pumps for the 
expulsion of drugs from the cell. In Escherichia coli, AcrAB-TolC proteins constitute the 
major chromosomally-encoded drug efflux system. AcrB, a trimeric membrane protein is 
well-known for its substrate promiscuity. It has the ability to efflux a broad spectrum of 
substrates alongside compounds such as dyes, detergent, bile salts and metabolites. 
Newly identified AcrB residues were shown to be functionally relevant in the drug 
binding and translocation pathway using a positive genetic selection strategy. These 
residues—Y49, V127, D153, G288, F453, and L486—were identified as the sites of 
suppressors of an alteration, F610A, that confers a drug hypersensitivity phenotype. 
Using site-directed mutagenesis (SDM) along with the real-time efflux and the classical 
minimum inhibitory concentration (MIC) assays, I was able to characterize the 
mechanism of suppression. 
Three approaches were used for the characterization of these suppressors. The 
first approach focused on side chain specificity. The results showed that certain 
suppressor sites prefer a particular side chain property, such as size, to overcome the 
F610A defect. The second approach focused on the effects of efflux pump inhibitors. The 
results showed that though the suppressor residues were able to overcome the intrinsic 
defect of F610A, they were unable to overcome the extrinsic defect caused by the efflux 
pump inhibitors. This showed that the mechanism by which F610A imposes its effect on 
AcrB function is different than that of the efflux pump inhibitors. The final approach was 
to determine whether suppressors mapping in the periplasmic and trans-membrane 
ii 
domains act by the same or different mechanisms. The results showed both overlapping 
and distinct mechanisms of suppression. 
To conclude, these approaches have provided a deeper understanding of the 
mechanisms by which novel suppressor residues of AcrB overcome the functional defect 
of the drug binding domain alteration, F610A. 
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CHAPTER 1 
INTRODUCTION 
 
Antibiotics Resistance: A Global Health Concern  
The discovery of penicillin, commonly known as the “miracle drug”, by 
Alexander Fleming in 1929, ushered in the era of antibiotics (Fleming, 1942). Within a 
decade after its discovery, the drug was mass-produced for the treatment of streptococcal, 
staphylococcal, and gonococcal infections.  As the drug became widely used, the 
inevitability of penicillin-resistant bacteria emerged. Penicillin-resistant Staphylococcus 
aureus was identified in the mid-1940s, just a few years after the release penicillin for 
therapeutic use. To date S. aureus continues to be a global health concern as newer β-
lactam drugs, such as methicillin, are no longer effective treatments (David and Daum, 
2010).  
The history of penicillin and penicillin-resistant S. aureus broadly describes the 
evolutionary race between antibiotics and resistant bacteria (Aminov, 2010; Alanis, 2005; 
Davies and Davies, 2010). The increase use of antibiotics has resulted in the emergence 
of resistant bacteria. And to overcome the resistant bacteria new antibiotics must be 
developed or discovered for treatment. Unfortunately, the development of drugs has not 
kept up with the spread of resistant bacteria. Also, antibiotics are extensively used, such 
in the livestock industry (Chuach, 2016; Aarestrup et al., 2001; Bywater et al. 2005) and 
even sometimes misused by clinician, physician and dentists globally (Weinstein, 2001; 
Monroe and Polk, 2000; Sweeney et al., 2004). The inappropriate uses even extend to the 
patients who do not understand appropriate dosage requirements (Okeke et al., 1999). 
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The combined issues of the lack of new antibiotics and the misuse of existing antibiotics 
have consequently allowed for the emergence of multi-drug resistant (MDR) bacteria 
such as Methicillin-Resistant Staphylococcus aureus (MRSA) and Carbapenem-resistant 
Enterobacteriaceae which are resistant to even the “last resort” antibiotics (Levy and 
Marshall, 2004; WHO 2014).  
Mitigation of the emergence of drug-resistance bacteria requires a fundamental 
understanding of the mechanisms by which the bacteria have adapted to an environment 
of excessive antibiotic use. Bacteria are constantly acquiring random mutations and 
mobile elements, such as plasmids, via horizontal gene transfer. When a bacterial 
population is exposed to selective pressures (e.g. in the presence of antibiotics) the 
majority of bacterial cells will be killed, while some will survive. Those that survived 
likely contain certain genetic variations that allowed them to overcome killing by the 
antibiotic. Therefore, certain specific genetic variations are beneficial because they allow 
bacterial survival under adverse conditions. This increases the fitness and the adapted 
genotype will be fixed with time.  
The acquisitions of resistance are evolutionary adaptations that act as a defense 
against antibiotics. There are four general modes of resistance bacteria utilize: (1) 
Alteration of the target protein to interfere with drug binding. For example, alteration in 
the DNA gyrase can lessen or eliminate the interaction of the clinically used 
fluoroquinolone antibiotics (Hooper, 1999; Mehla and Ramana, 2016). (2) Production of 
degradative enzymes such as β-lactamase, a periplasmic enzyme, which cleaves the β-
lactam ring of the antibiotic to inactivate antibiotic like penicillin (Abraham and Chain; 
1940). (3) Decrease in outer membrane (OM) permeability, such as the regulation of 
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porins expression to reduce influx of some antibiotics like β-lactams and 
chloramphenicol (Nikaido, 2003; Delcour, 2009). (4) Increase expression of antibiotic 
efflux pumps that actively export antibiotics into the extracellular space. MDR bacteria 
commonly utilize multiple mechanisms of antibiotic resistances simultaneously. Gram-
negative bacteria, however, have the advantage of synergy with outer membrane 
permeability barrier and the antibiotic efflux pumps. 
Efflux pumps have been classified into several superfamilies: ATP binding 
cassettes (ABC); major facilitator superfamily (MFS); multidrug and toxic-compound 
extrusion (MATE); small multidrug resistance (SMR); and resistance nodulation division 
(RND). The superfamilies differ based on energy used to export the substrates and their 
organization within the inner membrane or outer membrane. The ABC pumps use ATP 
for export while the other members use proton motive force via the proton gradient. The 
SMR and MFS are solitary pumps located in the cytoplasmic or inner membrane. MATE, 
ABC, and RND are tripartite systems, in which the inner membrane-localized efflux 
pump interacts with a periplasmic protein and an outer membrane protein (Li et al., 
2015). The tripartite systems are more efficient for resistance since the substrates are 
exported completely out of the cell into the extracellular space. The solitary pumps export 
substrates into the periplasm where the antibiotic can easily re-enter the cytoplasm. 
Resistance can be increased by tripartite systems capturing substrates exported by solitary 
pumps, therefore having a synergistic relationship (Lee et al., 2000). 
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AcrAB-TolC Efflux System 
The RND superfamily members are ubiquitous efflux systems of Gram-negative 
bacteria and are huge contributors for resistance of common antimicrobial compounds 
(Kumar and Schweizer, 2005). The Enterobacteriacea family is coincidently the largest 
family of Gram-negative bacteria that are multidrug resistant. AcrB, an archetypal 
member of the RND efflux pump family, is constitutively expressed proton-substrate 
antiporter and is the primary efflux pump utilized in Escherichia coli (Ma et al., 1995). 
AcrB, like other members of this superfamily, functions in a tripartite manner by 
interacting with AcrA, a periplasmic protein and TolC, which is the β-barrel outer 
membrane protein (Paulsen et al., 1997). AcrA is a member of the membrane fusion 
protein (MFS) superfamily (Dinh et al., 1994). It is a lipoprotein and hence anchored in 
the inner membrane through its amino terminus, while remainder of the protein is 
exposed in the periplasm. TolC is a multi-functional outer membrane protein, which, 
besides expelling antibiotics and other AcrB substrates out of the cell, also aid in the 
import of colicin E1, a toxin protein produced by certain E. coli strains (Masi et al., 2007) 
and export of α-hemolysin (Wandersman and Delepelaire, 1990).  
In the AcrAB-TolC efflux system all three proteins are essential for substrate 
efflux. The structure of each component has been solved (AcrA, Mikolosko et al., 2006; 
AcrB, Seeger et al., 2006 and Murakami et al., 2006; TolC, Koroakis et al., 2000). 
Molecular and biochemical approaches have shown direct interactions between AcrA to 
AcrB (Zgurskaya and Nikiado 2000), AcrA to TolC (Husain et al., 2004; Gerken and 
Misra, 2004) and TolC and AcrB (Tamura et al., 2005; Weeks et al., 2010). However, 
direct interaction between AcrB and TolC is controversial and currently the subject of 
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heavy debate. In a recent study, visualization of entire tripartite complex does not support 
a direct interaction between TolC and AcrB; however, it is worth noting that the 
recombinant tripartite complex used in this study was barely functional in vivo, thus 
leaves some room as to the full validity of their microscopy data (Du et al., 2015). 
 
AcrB and its Drug Binding and Translocation Pathway(s) 
The trimeric AcrB protein is highly dynamic in the drug binding and translocation 
pathways. Each AcrB monomer assumes three distinct conformational states during the 
rotation-peristaltic cycle (Seeger et al., 2006; Murakami et al., 2006). Regions of the 
AcrB monomer in the drug binding periplasmic domain (PD) rotates through three 
conformational states: access (A); binding (B) and extrusion (E) (Seeger et al., 2006; 
Murakami et al., 2006). This rotation is triggered by the proton relay network in the 
transmembrane domain (TMD). As the monomers proceed through the conformational 
states, the substrate travels through the defined pathway within each monomer. The drug 
translocation pathway begins with the access monomer, which has three entrances or 
channels: two facing the inner membrane and inner membrane/periplasm interface and 
one facing solely the periplasm (Murakami et al., 2006; Seeger et al., 2006; Husain et al., 
2011). Once the substrate has entered the access monomer, it is deposited in the proximal 
drug binding pocket, which is a large opening near the entrances. The second drug 
binding pocket, which is also known as the distal or the deep pocket, is closed in access 
monomer. However, it has been shown that depending on the size of a substrate, a 
substrate can reach the distal pocket while in the access monomer (Nakashima et al., 
2011; Eicher et al., 2012). For example, low molecular weight substrates like monocyclin 
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can enter directly into the distal pocket (Nakashima et al., 2011). Large molecular weight 
substrate like erythromycin will first enter the proximal pocket, and then as the access 
monomer shifts to the binding monomer conformation, it will move to the distal pocket 
(Nakashima et al., 2011). After the binding monomer shifts to the extrusion or exit 
monomer, the substrate then travels through the funnel-like opening near the upper-center 
portion of AcrB where it exits towards TolC for expulsion out of the cell.  
The AcrB drug binding and translocation pathway(s) are well-known for its 
promiscuity that allows for binding and efflux a broad spectrum of antibiotics and other 
substrates such as dyes, detergents (Nishino and Yamaguchi, 2001; Li et al., 2015), 
solvents (Tsukagoshi and Aono, 2000) bile salts, free fatty acids (Rosenberg et al; 2003) 
and metabolites (Ruiz and Levy, 2014). The mechanistic basis for promiscuity of AcrB is 
largely unknown since the inner anatomy and mechanisms of the drug binding and 
translocation are not well understood. Therefore, the endeavor to identify specific 
functional residues that affects the drug binding pockets and translocation of substrates is 
top priority. There are a number of investigations that use computational modeling and 
experimental approaches to unveil the properties and anatomy of the drug pockets and 
pathways. It is thought that promiscuity of AcrB is due to several key residues that line 
the drug translocation pathway and drug binding pockets. Some residues have already 
been identified in the drug pockets and pathways. For example, phenylalanine residues 
136, 178, 610, 615, 617 and 628 were identified via modeling to form a hydrophobic 
cluster in between the proximal and distal pockets (Seeger et al., 2006). Some of these 
residues make direct interaction with substrates. However, one residue Phe-610 (F610) 
was shown not to bind substrates directly, but when substituted with alanine (F610A) 
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caused a drug hypersensitive phenotype thus revealing its importance in AcrB function 
(Bohnert et al.,2008). It was later shown that F610A mutation altered the binding pocket 
position and hindered binding monomer from transitioning to extrusion monomer (Vargiu 
et al., 2011). F617, known as the “switch loop” residue, is unique in that its orientation is 
coupled to the proton motive force and this determines what state the monomer is in. 
When the adjacent residue Gly-616 (G616) was substituted to Asn (G616N) the switch 
loop’s flexibility was hindered thus resulting in the loss-of-conformational change from 
access to binding monomer (Cha et al., 2014). There are additional residues that are 
essential for AcrB activity, but are not located within the drug binding pocket. The proton 
relay network, which drives the conformational switch, has at least five key residues: 
Asp-407, Asp-407, Lsy-940, Arg-971 and Thr-987, all of which are located in the TM 
domain. These residues influence the drug binding/translocation pathway by supplying 
energy for conformational transition.  
A study carried out by Soparkar et al. (2015) identified seven functionally 
significant residues/sites in the drug binding and translocation pathway of AcrB. These 
residues/sites are the focus of this investigation. Henceforth, the term “site(s)” refers to 
the position of the residue in the amino acid sequence of AcrB. As mentioned above F610 
is a part of the phenylalanine cluster located within the pathway itself, but has not been 
shown to make direct contact with substrates (Bohnert et al., 2008). When substituted 
with alanine, F610A causes hypersensitivity to a number of substrates. Soparkar et al. 
utilized the hypersensitivity phenotype of F610A AcrB mutant to develop a positive 
selection strategy. By exposing AcrB F610A to selective pressures (i.e. antibiotics) they 
sought to isolate antibiotic resistant AcrB variants. The increase in resistance was due to 
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secondary mutations that suppress the hypersensitive phenotype conferred by F610A. 
The secondary mutations, or henceforth suppressors, identified were Tyr-49-Ser (Y49S), 
Val-127-Ala (V127A), Val-127-Gly (V127G), Asp-153-Glu (D153E), Gly-288-Cys 
(G288C), Leu-486-Trp (L486W), Phe-453-Cys (F453C). These substitutions in the 
presence of F610A, were able to alter the binding pocket or translocation pathway in such 
a way to reverse the defect caused by F610A.The mechanisms by which these 
substitutions overcome the defect were only minimally investigated. In this work, further 
research was carried out to examine the mechanisms by which suppressors function.  
 
Rationale and Goals of this Work 
The AcrB efflux pump, the primary exporter of antibiotics in Escherichia coli, has 
very broad substrate specificity. Its ability to recognize and export numerous unrelated 
substrates is thought to be due to highly flexible drug binding pockets and multiple drug 
translocation pathways. However, the complete anatomy of the drug binding pocket and 
translocation pathways are not fully clear. Several studies have identified AcrB residues 
that directly or indirectly influence the translocation pathway (Bohnert et al., 2008; 
Husain and Nikaido 2010; Koayashi et al., 2014; Nakashima et al., 2011; Eicher et al., 
2012; Soparkar et al., 2015). The residues identified by Soparkar et al. (2015) will be 
further characterized in this study. The AcrB alterations examined here are: Y49S, 
V127G, D153E, G288C, and L486W. The first four residues/sites are located in the 
periplasmic domain, while the last, L486W is located in the transmembrane domain (Fig. 
1). 
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The objective of this study is to characterize these suppressor residues in more 
detail to further investigate their abilities to overcome the defect caused by F610A. Three 
major aims were undertaken to characterize the suppressor residues. The first aim 
concerned the side chains specificities at a particular suppressor site. The second aim was 
to determine whether suppressors residues employ the same or different mechanisms to 
overcome the F610A defect. The third aim was to characterize the effects of efflux pump 
inhibitors on AcrB variants carrying suppressor alterations. Each aim is described in its 
corresponding chapter. 
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FIGURE 1: An AcrB monomer with suppressor mutations AcrB 
X-ray crystallography structure acquired from Protein Data Bank 
(2GIF). Locations of AcrB suppressors and position of F610 are 
depicted in color.   
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CHAPTER 2 
AIM 1: SIDE-CHAIN SPECIFICITY OF SUPPRESSORS  
 
Of the seven suppressors—Y49S, V127A, V127G, D153E, G288C, F453C and 
L486W—some had drastic changes in side chain properties, while others were very 
similar to the native residue. We asked whether drastic changes in the side chain 
properties are necessary for suppression. The two suppressors examined here were Y49S 
and D153E. These suppressors were chosen based on drastically differing side chain 
characteristics from the original residue to overcome the F610A defect.  
 
Suppressor Y49S 
Y49 is located near the exit tunnel of AcrB (Fig. 1). The native tyrosine (Y) residue 
has a large side chain with a benzene ring and a hydroxyl group. The suppressor 
substitution of serine (S) on the other hand has a small side chain with only the hydroxyl 
group. At this site, it was hypothesized that to overcome the F610A defect, a residue with 
a small side chain may be preferred so as to reduce spatial hindrance. To test this 
hypothesis, two variants were created via site-directed mutagenesis: Y49A and Y49F in 
the F610A background. The first variant contains an alanine (A) substitution and the 
second replaces Y with phenylalanine (F). Alanine, with only a small side chain (a 
methyl group) resembles serine in terms presenting low spatial hindrance, while 
phenylalanine with a large side chain is similar to the original tyrosine residue in terms of 
high spatial hindrance. If the side chain volume is the main determinant of suppression, 
then we predict that alanine substitution at Y49 will be able to suppressor F610A’s 
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defect. In contrast, the phenylalanine substitution at Y49 is expected not to be able to 
reverse the F610A defect just as the native tyrosine residue. The real-time NPN efflux 
and minimum inhibitory concertation (MIC) assays were used to characterize the 
mutants. 
The NPN efflux rates were calculated as changes in the NPN fluorescent intensity 
(arbitrary units) over time in seconds (Δa.u./Δs) (Fig. 2; Tables 1 and 2). The 
F610A+Y49A mutant had an efflux rate of -3.42±0.16 Δa.u./Δs and this rate was very 
similar to that of the F610A+Y49S mutant (-3.31±0.17 Δa.u./Δs). Moreover, these rates 
were nearly threefold better than that of the F610A mutant (-1.37±0.071 Δa.u./Δs). In 
contrast to Y49S, the presence of an Y49F substitution in the F610A background only 
modestly improved efflux rate (-2.03±0.23 Δa.u./Δs compared to -1.37±.07 of F610A). 
The tefflux 50% values mirrored the efflux rates trends for the mutants (Table 1).  
The MIC data in general followed the similar pattern as the NPN efflux assay. The 
alanine substitution at Y49A and the original suppressor Y49S both had identical MIC 
values for novobiocin (64 µg/mL) and erythromycin (32 µg/mL). These values are four 
(for novobiocin) and eight (for erythromycin) fold higher than the MIC values of the 
F610A mutant. It should be noted that any MIC value of two-fold or higher is considered 
significant. Unlike the Y49S and Y49A substitutions, the Y49F substitution only made a 
modest improvement in MIC values, increasing them by twofold over that displayed by 
the F610A mutant (Table 3). 
The effects of various substitutions at site 49 of wild-type AcrB in the absence of 
F610A were examined to see how they influence wild-type function. As seen in Figure 
2B and Table 2, the original suppressor Y49S displayed biphasic kinetics. That is, an 
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initial slow efflux rate in the first 25 s followed by a faster rate in the next 25 second.  In 
spite of this, however, MIC values were similar to wild-type (Table 4). In contrast, Y49A 
and Y49F substitutions acted very similarly to wild-type both in NPN and MIC assays. 
Together, these data showed that while the natural suppressor substitution of Y49S works 
best in the F610A background, by itself it produces the most deleterious effect on AcrB 
structure/function. Moreover, the data suggested that a smaller side chain residue is 
preferred at site 49 for suppressing the F610A defect.
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FIGURE 2: NPN efflux assays of Site 49 mutant variants. Bacterial cells were 
treated with CCCP to de-energize the inner membrane thus deactivating AcrB, then 
treated with NPN fluorescence dye. NPN dye integrate within the cellular 
membrane and emits with higher fluorescence intensity. After the addition of 50 
mM of glucose at 100s time point, the cellular membrane is re-energized and AcrB 
efflux activity is restored. The negative slope reflects efflux rate of AcrB exporting 
NPN dye into the aqueous solution. A. The suppressor Y49S, which overcome the 
F610A drug binding defect, significantly improved NPN efflux. Two additional 
mutants, carrying Y49F and Y49A in the F610A background, were tested. B. All 
AcrB substitutions shown in A were also tested in wild-type AcrB background. The 
native suppressor Y49S displayed a biphasic efflux rate, meaning in the first 25 
seconds the rate was much slower than in the next 25 seconds. These rates were 
significantly lower than that of wild-type or the other two variants, Y49A and Y49F. 
Quantitative values of efflux rate are listed in Tables 1-4.  
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TABLE 1 NPN Efflux rates and tefflux 50% values for Site 49 in F610A background. 
Values were derived from graphs depicted in Fig 2A.  
 NPN Efflux 
Mutants Variants 
Efflux rate 
(Δa.u/Δs) 
tefflux 50% (s) 
F610A -1.37±0.071 48.30± 1.50 
F610A+Y49A -3.42±0.16 20.80±1.26 
F610A+Y49F -2.03±0.23 34.55± 2.38 
F610A+Y49S -3.31±0.17 20.05± 4.08 
 
TABLE 2 NPN Efflux rates and tefflux 50% values for Site 49 in wild-type background. 
Values were derived from graphs depicted in Fig 2B.  
 NPN Efflux 
AcrB Mutants 
Variants 
Efflux rate   
(Δa.u/Δs) 
tefflux 50% (s) 
(AcrB-WT) -8.41±1.52 11.17± 1.64 
Y49S -1.19±0.38; -3.42±0.14
a 
38.80± 5.91 
Y49A -7.28±1.24 25.05±0.82 
Y49F -7.77±1.14 24.80±2.06 
a
 Two efflux rates represent the biphasic slope, as shown in Fig. 2B.  
TABLE 3 MIC values for Site 49 in F610A background. The mutants were used to 
examine side chain characteristics at site 49 of AcrB-F610A background.  
 MIC (µg/mL) 
AcrB Mutants 
Variants 
Novobiocin Erythromycin 
F610A 16 4 
F610A+Y49A 64 32 
F610A+Y49F 32 8 
F610A+Y49S 64 32 
 
TABLE 4 MIC values for Site 49 in wild-type background. The mutants used to examine 
side chain characteristics at site 49 of AcrB wild-type background. 
 
 MIC (µg/mL) 
AcrB substitution 
(Single Mutants) 
Novobiocin Erythromycin 
(AcrB-WT) 128-256
 
256 
Y49S 128-256 128 
Y49F 128-256 256 
Y49A 128-256 128-256 
 
 
16 
Suppressor D153E 
 
Similar approaches were carried out to analyze site 153 just as described above 
for site 49. Here, instead of the side chain volume, the side chain charge/polarity was 
evaluated. The site 153 is located near the drug binding pocket (Fig. 1). The native 
residue is aspartic acid (D) whose side chain is negatively charged. Surprisingly, its 
substitution with another negatively charged residue glutamic acid (E) overcomes the 
F610A-conferred hypersensitivity phenotype. In other words, even though both residues 
are negatively charged, they yield drastically different effects on the function of the 
mutant AcrB protein. To analyze this site further, two additional variants were generated 
by SDM: D153A and D153K in F610A and wild-type backgrounds. The former has an 
alanine (A) substitution, thus creating a neutral and small side chain at this site. The latter 
mutant contains a lysine (K) residue, thus replacing the negative charge of the native 
residue at this site with a positive charge. 
The real-time NPN efflux and MIC assays were employed to characterize these 
mutants. The NPN efflux assay data showed slight differences between the mutants. The 
original suppressor substitution of D153E and the lysine substitution at this site (D153K) 
had the similar efflux rates of -2.34±0.03 Δa.u./Δs and -1.97±0.26 Δa.u./Δs, respectively. 
The tefflux 50% value of F610A+D153K (46.80± 3.77 s) was, however, very similar to the 
hypersensitive mutant F610A (48.30± 1.50 s). The alanine substitution at this site 
(D153A) had a lower efflux rate of -1.44±0.178 Δa.u./Δs, which was close to the value of 
-1.37±0.06 Δa.u./Δs displayed by the hypersensitive mutant F610A without any 
suppressor substitution. The tefflux 50% value of F610A+D153A was higher than F610A 
mutant (Table 5).  
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In contrast to the data from the NPN efflux assay, the MIC data showed that both 
variants (D153A and D153K) in the F610A background significantly improved AcrB 
function. For novobiocin, both elevated MICs by twofold but for erythromycin they 
elevated MICs by eightfold (D153A) and fourfold (D153K) over that of the F610A 
mutant alone. In general, the mutant with the original suppressor substitution (D153E) 
performed better than the other two variants and this is consistent with the NPN efflux 
data. The fact that the D153A+F610A mutant did slightly better than the D153K+F610A 
mutant in the MIC assay in contrast to the NPN efflux assay may reflect a slightly 
different behavior of the two mutants against different substrates used in the two assays. 
In addition, the kinetic (NPN efflux) versus steady-state (MIC) measurements may reveal 
slightly different functional behaviors of the mutants.  
The effect of various alterations at site 153 in the absence of F610A was 
examined to see how these changes by themselves influence wild-type AcrB function. 
The original suppressor alteration of D153E slightly reduced the NPN efflux rate 
compared to the wild-type strain (Fig. 3B and Table 6). In contrast, both D153A and 
D153K more drastically lowered the NPN efflux rate over the wild-type strain, indicating 
that they impose a substantial structural/functional perturbation on the wild-type AcrB 
protein compared to the natural D153E suppressor alteration. Unlike the obvious 
quantitative differences in NPN efflux rates displayed by the three 153 site alterations, 
they behaved very similarly in the MIC test, thus highlighting the significance of 
conducting independent tests to reveal possible functional differences caused by various 
alterations in AcrB.  
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Both sites 49 and 153 require a particular side chain property to overcome the 
defect caused by F610A alteration within the drug binding pocket. The data for site 149 
clearly indicated a preference for small side chain for suppression. However, the 
preference at site 153 was not immediately obvious because both the native and 
suppressor side chains were negatively charged. It is possible that besides the negative 
charge, which does not appear to be strictly required, a slightly lager glutamate over 
aspartate may initiate necessary interactions required for suppression. Regardless of the 
exact mechanism of suppression, the data of suppressor alterations in wild-type AcrB 
indicate significant structural changes that are beneficial in the mutant background but 
detrimental in the wild-type background. 
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FIGURE 3: NPN efflux assays of Site 153 mutant variants. NPN efflux assays 
examining the polarity characteristics of site 153. The native residues of aspartic acid 
(D), a negatively charged residue, was substituted for another negatively charged 
residue glutamic acid (E). The mutant variants generated replaced D153 a positive 
charged residue lysine (K) and a neutral residue alanine (A). A. In the presence 
F610A, the native suppressor D153E and the mutant variant D153K had similar efflux 
rates; however, D153K had similar tefflux50% to F610A. D153A had efflux rate similar 
to F610A and a greater tefflux50%. B. In the absence of F610A defect, the negatively 
charged residues D153 and E153 were preferred over others, with the positively 
charged residue was least preferred residue at this site. Quantitative values of efflux 
rates and tefflux50% are listed in Tables 5-8.  
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TABLE 5 NPN Efflux rates and tefflux 50% values for Site 153 in F610A background. 
Values were derived from graphs depicted in Fig 2A. 
 NPN Efflux 
AcrB Variants 
Efflux rate   
(Δa.u/Δs) 
tefflux 50% (s) 
F610A -1.37±0.07 48.30± 1.50 
F610A+D153A -1.44±0.18 61.55± 3.00 
F610A+D153K -1.97±0.26 46.80± 3.77 
F610A+D153E -2.34±0.027 34.05±1.15 
 
 
TABLE 6 NPN Efflux rates and tefflux 50% values for Site 153 in wildtype background. 
Values were derived from graphs depicted in Fig 2B. 
 NPN Efflux 
   
AcrB Variants  
Efflux rate 
(Δa.u/Δs) 
tefflux 50% (s) 
AcrB-WT -8.41±1.52 11.17± 1.64 
D153A -3.28±0.65 38.05±1.00 
D153K -2.96±0.47 45.05±0.82 
D153E -4.76±1.18 15.30±3.30 
 
TABLE 7 MIC values for Site 153 in F610A background. The mutants used to examine 
side chain characteristics at site 153 of AcrB wildtype background. 
 
 MIC (µg/mL) 
AcrB Variants Novobiocin Erythromycin 
F610A 16 4 
F610A+D153A 32 32 
F610A+D153K 32 16 
F610A+D153E 64 32-16 
 
TABLE 8 MIC values for Site 153 in wildtype background. The mutants used to 
examine side chain characteristics at site 153 of AcrB wildtype background. 
 
 MIC (µg/mL) 
AcrB Variants Novobiocin Erythromycin 
(AcrB-WT) 256/128 256 
D153A 256/128 128 
D153K 128/64 128/64 
D153E 256/128 64 
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CHAPTER 3 
AIM 2: MECHANISM OF SUPPRESSION BY PERIPLASMIC AND 
TRANSMEMBRANE DOMAIN ALTERATIONS 
 
As mentioned in above in Aim 1, the seven suppressors of the AcrB mutant 
(F610A) mapped in six locations throughout the AcrB protein. Five mapped within the 
periplasmic domain (PD) and two within the transmembrane domain (TMD). The PD 
suppressors were expected to arise since F610A directly affects the periplasmic drug 
binding pocket. The TMD suppressors were less expected because they are a long 
distance from the known drug binding pockets, and the main function of TMD is to 
energize the protein via the proton relay network. Therefore, suppressors mapping within 
the TMD likely overcome the PD defect through an indirect mechanism. All suppressors 
increased drug resistance as shown in their MIC values and NPN efflux rates (Soparkar et 
al., 2015). However, unlike the PD suppressors, the TMD suppressors were not able to 
improve nitrocefin efflux where substrate affinity was also measured (Soparkar et al., 
2015). Since some suppressors were able to improve nitrocefin affinity while others 
could not, this indicates that at least two different mechanisms exist to overcome F610A 
defect. In this aim, we further characterized some of these suppressors to determine the 
mechanism by which they act. The following rationale was used to discern the 
mechanisms: if PD and TMD suppressors act through the same mechanism, their 
combined effects in reversing the F610A defect may not be additive. One other hand, if 
the two suppressors act through independent mechanism then their combined effects may 
22 
be additive. A third scenario is possible where by the two suppressors may interfere with 
each other’s mechanism, thus produce a negative phenotype when combined. 
To test these possibilities, triple mutants were generated via site-directed 
mutagenesis. An individual PD suppressor mutation was introduced into the F610A 
mutant acrB gene already bearing one of the TMD suppressors. The phenotypes of the 
triple mutants were then compared with the double mutants containing the individual 
suppressors in the F610A background. The PD suppressors used in this aims were 
V127G, D153E, G288C; while L486W was used as the TMD suppressor. A triple mutant 
with PD suppressor Y49S and TMD suppressor L486W could not be created despite 
repeated efforts.  
 
PD Suppressor V127G and TMD Suppressor L486W 
The PD suppressor alteration of V127G is located within the PN1 sub-domain of 
the AcrB protein. This location is not directly within the drug binding pocket (Fig. 1). 
The NPN assays carried out with this triple mutant showed biphasic efflux kinetics (Fig. 
4; Table 9). That is, an initial slow efflux rate (-0.93±0.19 Δa.u./Δs) in the first 25 s 
followed by a faster rate (-2.10±0.18 Δa.u./Δs) in the next 25 second. Both rates were 
lower than the rates of the two double mutants, F610A+V127G (-2.72±0.34 Δa.u./Δs) and 
F610A+L486W (-2.97±0.18 Δa.u./Δs). Furthermore, the tefflux 50% value was significantly 
higher for the triple mutant than the double mutant (Table 9). These data suggest that the 
PD suppressor V127G and the TMD suppressor L486W act somewhat antagonistically 
with respect to their abilities to overcome the NPN efflux defect conferred by F610A.  
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Unlike the NPN efflux assays, the MIC data were less clear with regards to 
establishing the antagonistic relationship between V127G and L486W (Table 10). In this 
assay, the MIC values of the triple mutant for both novobiocin and erythromycin 
improved to resemble that of the F610A+V127G mutant, showing the dominance of the 
V127G-mediated suppression over that mediated by L486W. 
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FIGURE 4: NPN efflux assays of periplasmic V127G and transmembrane L486W 
mutants. The triple mutant containing the periplasmic domain (PD) suppressor 
V127G, transmembrane domain suppressor (TMD) L486W and the hypersensitive 
mutant F610A showed to be more defective than the double mutants. The triple 
mutant also showed a biphasic slope. The first ~25s had an efflux rate nearly equal to 
the F610A alteration, then the following ~25s the efflux rate increased, yet still not 
as efficient as the double mutants. The data showed an antagonistic behavior of 
V127G and L486W in the F610A background. Quantitative values of efflux rates 
and tefflux50% are listed in Table 9.  
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TABLE 9 Efflux rates and tefflux 50% values of PD suppressor V127G and TMD 
suppressor L486W mutant variants 
 NPN Efflux 
AcrB Variants 
Efflux rate 
(Δa.u/Δs) 
tefflux 50% (s) 
WT -8.00± 0.72 11.55± 1.29 
F610A -1.20±0.12 39.55±5.07 
F610A+L486W -2.97±0.18 22.30± 2.22 
F610A+V127G -2.72±0.34 24.38± 4.08 
F610A+V127G+L486W -0.93±0.19; -2.10±0.18
a 
43.68± 4.90 
a
 The two efflux rates from the biphasic slope of the triple mutant is deduced from Fig. 4.  
 
 
Table 10 Minimum Inhibitory Concentration (MIC) values of periplasmic suppressor 
V127G and transmembrane suppressor L486W mutants 
 
 MIC (µg/mL) 
AcrB Variants Novobiocin Erythromycin 
WT 128 128 
F610A 8 2 
F610A+L486W 32 16 
F610A+V127G 64 32/64 
F610A+V127G+L486W 64 32/64 
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PD Suppressor D153E and TMD Suppressor L486W 
In contrast to the V127G and L486W combination, when the PD suppressor 
D153E, located in the PN2 sub-domain of AcrB, was combined with the TMD suppressor 
L486W in the F610A background, the outcome was additive. As shown in Figure 5 and 
Table 11, the NPN efflux rate (-4.54±032Δa.u./Δs) of the triple mutant 
F610A+D153E+L486W was higher than the double mutants F610A+D153E (-2.02 
±0.52Δa.u./Δs) and F610A+L486W (-2.97±0.18 Δa.u./Δs). Consistent with the NPN data, 
the simultaneous presence of the two suppressor alterations in the F610A background 
significantly improved the MIC values of the mutant AcrB protein for both novobiocin 
and erythromycin (Table 12). These data suggest that the PD suppressor (D153E) and 
TMD suppressor (L486W) act via independent and non-interfering mechanisms to 
partially reverse the F610A defect. 
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FIGURE 5 NPN Efflux assays with periplasmic D153E and transmembrane L486W 
mutants. The PD suppressor D153E and TMD suppressor L486W in combination 
with F610A demonstrated an additive effect as the rate of the triple mutant is nearly 
twice that of the double mutant; however, the efflux rate is not equal to wild-type, 
meaning there is still some defect either caused by the F610A alteration or the 
combined PD and TMD alterations. Quantitative values of efflux rates and tefflux50% 
are listed in Table 11. 
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Table 11 NPN efflux rates and tefflux 50% (s) of periplasmic suppressor D153E and 
transmembrane suppressor L486W mutant variants. 
 NPN Efflux 
AcrB Variants 
Efflux rate   
 (Δa.u/Δs) 
tefflux 50% (s) 
WT -8.00 ± 0.72 11.55± 1.29 
F610A -1.20±0.12 39.55±5.07 
F610A+L486W -2.97±0.18 22.30± 2.22 
F610A+D153E -2.02± 0.52 31.38± 3.21 
F610A+D153E+L486W -4.54±0.32 24.80± 2.06 
 
 
Table 12 MIC values of periplasmic suppressor D153E and transmembrane suppressor 
L486W.  
 
 MIC (µg/mL) 
AcrB Variants Novobiocin Erythromycin 
WT 128 128 
F610A 8 2 
F610A+L486W 32 16 
F610A+D153E 32 16 
F610A+D153E+L486W 64 32 
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PD Suppressor G288C and TMD Suppressor L486W 
G288 is located directly within the distal drug binding pocket just as the F610 
residue (Table 1). The triple mutant F610A+G288C+L486W had an efflux rate (-
7.41±0.69 Δa.u./Δs) similar to that of wild-type (-8.00±0.72 Δa.u./Δs) and 
F610A+G288C (-6.42±1.07Δa.u./Δs), but significantly better than F610A+L486W (-
2.97±0.18). The MIC data for erythromycin follow the similar trend as the NPN efflux 
data (Table 14). G288C has been shown to reverse F610A defects better than any other 
suppressors identified (Soparkar et al., 2015), suggesting that the G288C alteration 
creates the most preferred mechanism to overcome F610A defect. Since the 
F610A+G288C+L486W triple mutant displays a much better NPN efflux rate and MIC 
than the F610A+L486W mutant, the G288C mechanism appears to dominate over that of 
L486W. 
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FIGURE 6 NPN Efflux assays with periplasmic G288C and transmembrane L486W 
mutants. The PD suppressor G288C and TMD suppressor L486W had an efflux rate 
and tefflux 50% very similar to wild-type and the double mutant containing F610A and 
G288C alterations (Table 13). G288C suppressor has been shown previously to be the 
dominate suppressor out of the seven F610A suppressors (Soparkar et al., 2015). Its 
mechanism does not seem to be affected by the presence of L486W alteration. 
Quantitative values of efflux rates and tefflux50% are listed in Table 13. 
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Table 13 Efflux rates of PD suppressor G288C and TMD suppressor L486W mutant 
variants 
 
 NPN Efflux 
AcrB Variants 
Efflux rate 
(Δa.u/Δs) 
tefflux 50% (s) 
WT -8.00± 0.72 11.55± 1.29 
F610A -1.20±0.12 39.55±5.07 
F610A+L486W -2.97±0.18 22.30± 2.22 
F610A+G288C -6.42±1.07 12.55± 2.08 
F610A+G288C+L486W -7.41±0.69 16.05± 3.46 
 
 
Table 14 Minimum Inhibitory Concentration (MIC) values of periplasmic suppressor 
G288C and transmembrane suppressor L486W. 
 
 MIC (µg/mL) 
AcrB Variants Novobiocin Erythromycin 
WT 128 128 
F610A 8 2 
F610A+L486W 32 16 
F610A+G288C 64 32 
F610A+G288C+L486W 64 64 
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Effects of suppressors alterations on wild-type AcrB function 
The effects of the suppressor alterations were examined in the wild-type AcrB 
background to see whether they influence AcrB function in the absence of F610A. To do 
this, the F610A alteration was converted back to wild-type F in the AcrB proteins 
containing either single or two suppressor alterations. The NPN efflux assays (Fig. 7A) 
showed V127G+L486W (-6.78 ±0.69Δa.u. /Δs) had similar rate to wild-type (-8.00 ± 
0.72Δa.u./Δs). Also, the AcrB protein containing either one of the two suppressors 
behaved like wild-type AcrB (Fig.7A). Thus, these suppressors alterations in the wild-
type background do not substantially affect AcrB function. 
The presence of D153E in the wild-type AcrB protein significantly lowered NPN 
efflux rate, reducing it from -8.00±0.72 Δa.u./Δs for wild-type to -3.77±0.15 Δa.u./Δs 
with D153E (Fig. 7.B). In contrast to D153E, L486W reduced efflux rate only nominally 
to -6.04±0.08. When both alterations were present, the rate was similar to D153E alone 
(Fig 7B, Table 15). Thus, whereas both D153E and L486W produce positive effects in 
the F610A mutant background, their presence either alone or together is either somewhat 
(L486W) or significantly (D153E or D153E+L486W) deleterious in the wild-type AcrB 
background. The influence of D153E is dominant over the effect of L486W. Unlike the 
NPN efflux data, in the MIC assay, the D153E+L486W mutant behaved similarly to 
wild-type. 
Together, it can be concluded that D153E significantly and negatively impacts 
wild-type AcrB function. Like D153E, the presence of G288C, one of the strongest 
suppressors of F610A, had a significantly negative effect on NPN efflux and this effect 
was dominant over that of L486W, which by itself only modestly affected efflux (Table 
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15; Fig. 7C). The strong negative effect is indicative of significantly structural changes 
within AcrB which when imposed in the F610A background have a positive effect on 
protein’s function while enduring a negative functional effect in the wild-type AcrB 
background. 
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TABLE 15 Efflux rates tefflux 50% values of PD suppressor and TMD suppressor mutant 
variants in wild-type background 
 
 NPN Efflux 
AcrB variants 
Efflux rate 
(Δa.u/Δs) 
tefflux 50% (s) 
WT -8.00± 0.72 11.55± 1.29 
L486W -6.04±0.08 14.72±1.15 
V127G -7.77±0.69 12.38±0.58 
V127G+L486W -6.78±0.69 13.05±1.83 
D153E -3.77±0.15 24.55±1.29 
D153E+L486W -3.27±0.17 26.30±1.26 
G288C -3.55±0.18 28.30±2.50 
G288C+L486W -3.98±0.39 22.80±5.50 
 
 
 
TABLE 16 MIC values of PD suppressor and TMD suppressor mutant variants in wild-
type background 
 
 MIC (µg/mL) 
AcrB variants Novobiocin Erythromycin 
WT 128 128 
L486W 128 128 
V127G 128 128 
V127G+L486W 256 256 
D153E 128 128/64 
D153E+L486W 128 128 
G288C 128 64 
G288C+L486W 128 128 
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CHAPTER 4 
AIM 3: USE OF EFFLUX PUMP INHIBITORS TO PROBE ACRB ACTIVITY 
 
AcrB activity can be made defective by intrinsic or extrinsic means. The F610A 
intrinsically affects AcrB function, as determined by NPN efflux and MIC assays (see 
above). These defects in AcrB can be partially reversed by the intragenic suppressor 
alterations (Soparkar et al., 2015; see above). Efflux pump inhibitors (EPIs) represent 
extrinsic factors. EPIs, which are synthetic or natural compounds, can also decrease AcrB 
activities in a manner similar to the intrinsic defects, such as that caused by the F610A 
alteration. Both F610A and EPIs influence the same general region within the drug 
binding pockets of AcrB (Vargiu et al., 2011; Vargiu et al., 2014). The F610A alteration 
and EPIs, specifically phenylalanyl-arginine β-naphthylamide (PAβN) and 1-(1-
naphtylmethyl)-piperazine (NMP), were shown to either block substrate binding or 
hinder AcrB from undergoing conformational changes necessary for drug translocation 
(F610A, Vargiu et al., 2011; EPIs, Vargiu et al., 2014).  
Here, it is asked whether intragenic suppressors, which overcome the defect 
caused by F610A, can also overcome the defects in AcrB activity caused by PAβN and 
NMP. It was hypothesized that since both intrinsic and extrinsic factors negatively 
influence the drug binding pocket of AcrB, the intragenic AcrB suppressors may also 
overcome the defect caused by EPIs. On the other hand, if F610A and EPIs cause non-
overlapping defects, the suppressor alterations may not reverse the defect caused by EPIs.  
To test this hypothesis, NPN efflux assays were carried with AcrB variants 
carrying various suppressor alterations. As per protocol, glucose was added to initiate 
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NPN efflux. Two hundred seconds after the addition of glucose, when maximum NPN 
efflux was achieved, PAβN (20µg/mL) or NMP (40µg/mL) was added. The increase in 
NPN fluorescence intensity after the addition of EPIs reflects the efflux inhibition. If 
suppressor alterations prevent or reduce EPI’s action on AcrB, then NPN efflux would 
not be as severely inhibited. 
 
Effects of PAβN  
As seen in Figure 8 and Table 17, cultures expressing wild-type AcrB displayed a 
modest inhibition in NPN efflux (0.490±0.108 Δa.u./Δs). Surprisingly, in cultures 
expressing suppressor-containing AcrB variants, NPN efflux was more severely inhibited 
than in wild-type AcrB cultures. These data revealed that not only the suppressor 
alterations were unable to overcome the PAβN-mediated inhibition, their presence made 
the variant AcrB proteins more sensitive to this inhibitor than the wild-type AcrB protein. 
Overall, the F610A suppressor mutations were unable to overcome the inhibitory effect 
of PAβN. 
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Table 17 Rate of inhibition via efflux pump inhibitor PAβN.  
 
 NPN Efflux 
AcrB Varaints Rate of PAβN inhibition (Δa.u./Δs) 
WT 0.490±0.108 
Y49S 1.805±0.167 
V127G 1.066±0.264 
D153E 0.753±0.245 
G288C 0.978±0.163 
L486W 0.936±0.383 
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FIGURE 8: Modified NPN efflux assays with the efflux pump inhibitor (EPI) 
PAβN. PAβN was added after maximum efflux was reached at 200s. The graph 
shows that none of the F610A suppressor was able to overcome the inhibitory effects 
of PAβN. The rates of inhibition, i.e. the extent of positive slope, are listed in Table 
17.  
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Of the five suppressors tested, Y49S conferred most susceptibility to PAβN, with 
the rate of inhibition of 1.805±0.167 Δa.u./Δs that was almost fourfold higher than that of 
wild-type AcrB. In first aim of this study, three Y49 mutant variants were generated to 
examine the effect of side chain on F610A suppression. Those results revealed that a 
smaller side chain at site 49 is preferred for suppression. With these results in mind, it 
was asked as to how various side chains at site 49 affect PAβN susceptibility. To test this, 
the NPN/PAβN efflux assay was performed with cultures expressing either wild-type 
AcrB and the Y49A, Y49F or Y49S variant. Y49A and Y49S variants behaved similarly 
and were more susceptible to PAβN inhibition than the Y49F variant, which behave 
similar to wild-type. The data revealed that the presence of large side chains (Y or F) 
confers greater resistance to PAβN than those with smaller side chains (S or A). These 
data inversely correlate with the suppression data in that small side chains are preferred 
for F610A suppression, but larger side chains are preferred for resistance against PAβN.  
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TABLE 18 Rates of Inhibition for Site 49 mutant variants 
 
 NPN Efflux 
AcrB Variants Rate of PAβN inhibition (Δa.u./Δs) 
WT 0.490±0.108 
Y49S 1.805±0.167 
Y49A 2.12±0.29 
Y49F 1.30±0.16 
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FIGURE 9: Modified NPN efflux assays with site 49 AcrB mutant 
variants. Y49S and Y49A mutants were strongly inhibited by the efflux 
pump inhibitor PAβN. The Y49F mutant was less susceptible than Y49S 
and Y49A, but slightly more susceptible than wild-type. Quantitative 
values of rates of inhibition are shown in Table 18. 
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Effect of NMP 
NMP inhibitor of AcrB protein was also used to ask if intragenic AcrB 
suppressors can overcome the effect of extrinsically added inhibitors. NMP (40 µg/mL) 
was added after the strains reached maximum NPN efflux. The NMP was found to be less 
effective in inhibiting AcrB than PAβN; nevertheless, a difference between wild-type and 
AcrB variants with suppressor alterations were noticeable (Fig. 10 and Table 19). The 
rate of inhibition for wild-type was 0.082±0.036 Δa.u./Δs. The suppressor mutants had 
inhibition rates twofold to threefold higher than wild-type. Just as the case with PAβN, 
the suppressor alterations were unable to overcome the inhibitory effects NMP and in fact 
conferred greater sensitivity than the wild-type AcrB protein.  
 
These data indicated that the defect caused by F610A on AcrB function is not 
similar to that caused by EPIs. This was somewhat surprising since both F610A and EPIs 
used here, PAβN and NMP, are thought to affect the drug binding pocket. A closer 
examination of the exact binding sites of PAβN and NMP and the structural alterations 
caused by F610A may provide better understanding of their effects on AcrB. 
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Table 19 Rate of inhibition via efflux pump inhibitor NMP 
 
 NPN Efflux 
AcrB Variants Rate of PAβN inhibition (Δa.u./Δs) 
WT 0.082±0.036 
Y49S 0.275±0.038 
V127G 0.320±0.077 
D153E 0.34±0.026 
G288C 0.245±0.058 
L486W 0.31±0.013 
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FIGURE 10: Effects of NMP-mediated inhibition of NPN efflux. Though the 
rates of inhibition are not as drastic as seen with PAβN (Fig 8) the conclusions 
are the same. The suppressor alterations were unable to over the inhibitory effects 
of NMP. Rates of inhibition are shown in Table 19.  
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CHAPTER 5 
DISCUSSION 
 
The aim of this work was to investigate the mechanisms employed by the intragenic 
suppressor mutations that overcome the AcrB drug binding pocket defect caused by the 
F610A alteration. This alteration was shown via computational modeling to alter the 
dimensions of the drug binding pocket (Vargiu et al., 2011). Moreover, functional assays 
showed that the F610A alteration severely reduced the affinity of AcrB to nitrocefin; 
while all PD suppressors, but not TMD suppressors, reversed this defect (Soparkar et al., 
2015). The three main aims were (1) determine side chain specificity of suppressor 
residues, (2) determine whether PD and TMD suppressors employ same or distinct 
mechanisms to over the F610A defect and (3) probe the effect of efflux pump inhibitors 
on mutant and wild-type AcrB proteins.  
 
Side Chain Specificity 
In this work side chain specificities of sites Y49 and D153 were characterized. 
(Specificity of site S288 were previously characterized in our lab by Soparkar et al., 
2015). To test the effect of side chain volume, two AcrB variants were created bearing 
Y49A and Y49F alterations in the wild-type or F610A background. The NPN efflux and 
MIC data showed that smaller side chains of A49 and S49 are preferred over that of 
bulky side chains of Y49 and F49 for suppression of the F610A-mediated defect. The 
bulkier side chain of Y and F may be less preferred because they may cause spatial 
hindrances with surrounding residues to restrict drug flow. This effect is more 
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pronounced in the F610A background where a partial collapse in the drug binding pocket 
may require conformational accommodation near or at the exit channel for the 
resumption of drug flow. Using the measurement tool of the Pymol software program, a 
close interaction, via hydrogen bond, between with Y49 in the binding monomer and 
R239 in the extrusion monomer can be predicted in the wild-type background (Fig. 11). 
This interaction is not possible in the any other monomers. When Y49 is changed to 
serine, as in the suppressor mutant, the interaction between S49 and R239 becomes 
highly unlikely due to long distance between the hydrogen bonding atoms of the two 
residues (Fig. 11). It is possible that the lack of this molecular interaction between the 
binding and extrusion AcrB monomers suppresses the F610A defect. In future, this 
possibility can be tested by making alterations at R239. Unlike Y49, the side chain of F49 
cannot engage with R239 through hydrogen bonding. Yet the two residues behave 
similarly in all tests performed in this work. Therefore, a bulky side chain at position 49 
may also be involved in tight packing near the exit channel. This packing is disrupted 
when substituted with small residues S or A, which are beneficial in the F610A 
background (causing suppression) but somewhat deleterious in the wild-type background 
by affecting local folding or packing. 
Unlike the Y49S substitution, D153E does not dramatically alter the side chain 
property at this site, yet E153 suppresses F610A defect whereas D153 does not. Glutamic 
acid does have a small size difference from aspartic acid because of an additional carbon 
in the side chain, however the two residues share the same negative charge. The site 153 
is located near the drug binding pocket, but is not within the drug binding pocket. To 
investigate the effect of charge and volume at site 153 on F610A suppression, two 
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additional AcrB variants were generated bearing a D153K or D153A substitution. In 
contrast to D153E, the two mutant variants only slightly reversed the F610A defect as 
assessed by NPN efflux assays. The presence of the positively charged residue lysine at 
position 153 (D153K) was better at repairing the F610A defect than the neutral and small 
side chain (D153A). These findings indicated (1) longer polar side chains (E153 or K153) 
are preferred over smaller polar (D153) or apolar (A153) side chains for suppressing the 
F610A defect, and (2) negatively charged side chain of E153 is preferred over positively 
charged side chain of K153. It is currently not known why substituting D153 with a 
somewhat longer negative side chain of E153 is beneficial in the F610A background. The 
presence of any three substitutions (D153E, D153K or D153A) conferred somewhat 
negative effect on wild-type AcrB activity as assessed by NPN efflux assays. This 
indicated that conformational changes that are beneficial in the mutant AcrB background 
are somewhat detrimental in the wild-type AcrB backbone.  
Future experiments can be designed to further examine the side chain volume and 
charge at site 153. To examine the effect of volume at this site, two mutants containing 
asparagine-153 (N153) and glutamine-153 (Q153) could be generated. The former 
resembles the wild-type residue aspartic acid and the latter resembles the suppressor 
glutamic acid. If volume is of importance to overcoming the F610A alteration, then Q153 
mutant should suppress just as E153, while N153, like D153, should not. However, if 
charge is a necessary at this site, then neither Q153 nor N153 would overcome F610A 
defect.  
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FIGURE 11 Molecular image of AcrB sites using Pymol program. A) 
Depict a possible interaction between the native tyrosine-49 (Y49) and 
arginine-239 (R239). The approximate distance of 2.7Å between the 
oxygen of tyrosine and a nitrogen of arginine is optimum for hydrogen 
bond formation. B) The site 49 was computationally mutagenized using 
the feature of Pymol to serine (Y49S). The distance between the oxygen 
of serine and a nitrogen of arginine is approximately 6.4Å, which is too 
far for hydrogen bond. 
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Suppressor Mechanisms by Periplasmic and Transmembrane Domain Alterations 
Taken as a whole, the periplasmic domain (PD) suppressors—V127G, D153E and 
G288C—all behaved somewhat differently than the transmembrane domain (TMD) 
suppressor L486W in responding to the F610A defect. The PD suppressor V127G 
displayed an antagonistic relationship with L486W, indicating that they interfered with 
each other’s mechanism of suppression. The L486W alteration may indirectly influence 
the PD and this effect is somehow negated in the presence of the PD alteration V127G. In 
contrast, the D153E-mediated suppression mechanism showed a positive relationship 
with that of the L486W alteration. This indicated that the two alterations acted 
independently and in a non-interfering manner to overcome the F610A defect. Finally, 
the G288C-mediated suppression mechanism was dominant over that of the L486W 
alteration, indicating that they likely acted in the same pathway.  
As stated earlier, the PD binds and translocate drugs upon receiving conformation 
changes from the TMD which is involved in proton translocation. The F610A alteration 
is located in the drug binding pocket of PD. The L486W substitution likely directly 
influences the TMD, with or without affecting proton translocation, to then indirectly 
influence the PD to partly overcome the F610A defect. In contrast to L486W, the PD 
substitutions D153E and G288C likely directly influence the drug binding pocket to 
partly alleviate the F610A defect. Their mechanism of suppression is compatible with 
that of L486W. The V127G substitution of the PD is not in the vicinity but away from the 
drug binding pocket. How changes at V127 overcome the F610A defect is not known but 
its mechanism of suppression is not compatible that of the L486W substitution. 
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Effect of Efflux Pump Inhibitors on AcrB Variants Bearing Suppressor Alterations 
EPIs PAβN and NMP were shown to bind to the hydrophobic trap of the drug 
binding pocket via computational modeling (Vargiu et al., 2014). These interactions are 
thought to induce a physical distortion that hinders substrates from binding to the drug 
binding pockets (Vargiu et al., 2014). F610A is also thought to distort the drug binding 
pocket (Vargiu et al., 2011). The mechanism of distortion caused by the intrinsic F610A 
substitution and extrinsic factors like EPIs may or may not be similar. In this work it was 
hypothesized that if EPIs distort AcrB binding pocket in a manner similar to F610A, then 
suppressors alterations isolated against F610A may also overcome the inhibitory effect of 
EPIs in a wild-type AcrB background. This hypothesis was however not supported by the 
data presented in this study, as none of the suppressor alterations were able to overcome 
the efflux defect caused two different EPIs, PAβN and NMP. In fact, the suppressor 
alterations made the otherwise wild-type AcrB protein more susceptible to the effects of 
inhibitors. This would suggest that the drug binding pocket distortion caused by F610A is 
not similar to the distortion caused by EPIs PAβN and NMP. Although the results of this 
aim did not support the hypothesis stated in this work, it does however support the 
conclusions made in Vargiu et al. (2014) pertaining to the effect of some inhibitors and 
the F610A substitution. Their study characterized, via computational modeling, a novel 
synthetic inhibitor MBX2319. This inhibitor was compared with the inhibitors D13-9001, 
PAβN and NMP, as well as the F610A alteration. It was concluded that inhibitors 
MBX2319, D13-9001 and the F610A alteration similarly influence to the hydrophobic 
pocket that may hinder conformational change of AcrB. In future work, the two inhibitors 
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MBX2319 and D13-9001 could be used to ask if the suppressors repair the effects caused 
these inhibitors since their mechanism of damage seems to be similar. 
 
Conclusion 
In conclusion, attempts were made in this study to gain deeper insights into the 
mechanism of suppression. It was discovered that specific side chain properties (e.g. size 
and charge) within AcrB are important for the suppression of F610A defect. Suppressor 
residue side chains may either produce or disrupt specific interactions with neighboring 
residues to allow for necessary conformational accommodation and restoration of 
function. The multiplicity of the suppressor mechanisms was revealed by combining PD 
and TMD suppressors. In some instances, the TMD and PD suppressors acted 
synergistically (e.g. L486W and D153), while in others they acted antagonistically (e.g. 
L486W and D153). This showed that despite being located in the same domain, the PD 
suppressors acted by somewhat different mechanisms to overcome the drug pocket 
binding defect. The work underscored the structural flexibility of the AcrB protein to 
compensate for drug binding pocket defects and further reflected the well-known 
promiscuity of the protein. It was also determined that the inhibitory mechanism of 
F610A does not overlap with the inhibitory mechanism of some efflux pump inhibitors, 
namely PAβN and NMP. However, other inhibitors may provide different results. 
This research highlights the importance of combining genetic approaches with 
biochemical and structural approaches to better understand the major drug efflux 
mechanism. Deeper understanding of drug efflux mechanisms will aid future drug 
developments and novel therapeutics. For example, the investigation of the mechanism of 
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efflux inhibitors will possibly give rise to the development of adjuvant therapies (Nikaido 
and Pages, 2012; Blair et al, 2015; Dantzig et al, 2003). These therapies use EPIs in 
tandem with lower dosage of antibiotics to increase potency of antibiotics. Further work 
will be necessary for deeper knowledge of the suppressor mechanisms of AcrB residues 
and their implications in overcoming the effects of EPIs. 
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CHAPTER 6 
MATERIALS AND METHODS 
 
Bacterial Strains, Culture Conditions and Media 
All strains were derived from MC4100 Δara ΔacrAB::scar strain and are listed in 
Table 20. JM109 strain was used for creation of mutants using site-directed mutagenesis. 
Both MC4100 Δara ΔacrAB::scar and JM109 were made competent via Mn2+/Ca2+ 
(CCBM80) treatment as described by Hanahan et al. (1991). Competent cells were also 
stored at -80ºC until used for heat-shock transformation. Luria broth (LB) was prepared 
from Difco
TM
 LB broth Lennox and purchased from Becton Dickenson. Luria broth agar 
(LBA) contained LB and 1.5% agar. Both LB and LBA contained 12.5ug/mL 
chloramphenicol (CM) to maintain plasmid. Stains were incubated at 37ºC for 16-18hrs.  
 
Chemicals 
Chloramphenicol, novobiocin and erythromycin were purchased from Sigma 
Aldrich. Stock concentrations were 25 mg/mL for chloramphenicol and 56.76 mg/mL for 
novobiocin and erythromycin. N-phenyl-1-naphthylamine (NPN), carbonyl cyanide 3-
chlorophenylhydrazone (CCCP), 1-(1-napthylmethyl) piperazine (NMP), and 
phenylalanylarginine β-nahthylamide hydrochloride (PAβN) were also purchased from 
Sigma Aldrich. They were dissolved in 95% ethanol (NPN), DMSO (CCCP), HCl 
solution (98% of 0.1N HCl + 2% of 6N HCl) (NMP), and sterilized water (PAβN). All 
antibiotics and chemicals were stored at -20ºC. 
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Construction of Strains  
Mutations were introduced in the acrB gene that resides in the pACYC184 plasmid 
alongside wild-type acrA gene (pACYC184 is a low-copy-number plasmid). Mutations 
were introduced using the Quikchange Lightening site-directed mutagenesis (SDM) kit 
from Agilent Technologies. Plasmid concentration for SDM was 5 ng/µL. Primers 
concentration were 25 ng/µL. Primers for SDM are listed in Table 21. SDM reactions 
were carried out using a Eppendorf Mastercycler gradient machine. The cycling 
parameters are indicated in Table 22. After SDM reactions, the products were 
transformed into competent JM109 cells. Single transformant colonies were purified on 
LBA+CM plates. 5mL cell cultures (in LB+CM) from these colonies were used to extract 
and purify plasmid using the Qiagen Spin Miniprep Kit. acrB from purified plasmids 
were then sequenced at the Arizona State University DNA lab. Sequencing primers are 
listed in Table 23. DNA sequences were analyzed using DNAMAN Version 3.0 from 
Lynnon BioSoft. 
 
Minimum Inhibitory Concentration 
MICs were carried out as described in Soparkar et al. (2015). Novobiocin and 
Erythromycin were used to determine bacterial susceptibility. MICs were performed in 
96-well plates using a 2-fold dilution method. Wells were filled with LB+CM and then 
supplemented with the required antibiotic solution previously diluted in LB+CM. 
Overnight grown bacterial cultures were diluted 1:1000 (~10
6
 cells/ml). Twenty uL of 
diluted culture was added to each well, thus making the volume of cells plus antibiotic 
medium to be 200µL per well. Plates were rocked gently in 37ºC incubator for 18 hours. 
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After incubation, optical densities at 600 nm (OD600) of cultures were measured using 
VeraMax ELISA microplate reader from Molecular Devices. OD600 readings >0.1 were 
considered inhibitory for bacterial cells, while <0.1 were considered viable/live bacterial 
cells.  
 
NPN Efflux Assay 
The NPN efflux assays were carried out as described by Misra et al. (2015). Bacterial 
cells were cultured overnight for 17-18 hours, then pelleted at 3000 rpm for 10 minutes. 
Pellets were washed twice with phosphate buffer (20 mM potassium phosphate at pH 7.0 
+ 1mM magnesium chloride). Resuspended cells were then diluted 1:5 into phosphate 
buffer, i.e. 1 mL of bacterial culture to 4 mL of phosphate buffer. 4 mL of diluted 
cultures were transferred into a 15 mL-conical tube. The cells were treated for 15 minutes 
with 10 mM CCCP for a final concentration of 100 µM. Cells were washed twice with 4 
mL of phosphate buffer each time. Cells were then treated for 15 minutes with 1 mM 
NPN for a final concentration of 10 µM. Then they were transferred into fluorescence 
cuvette and placed in Cary Eclipse Fluorescence Spectrophotometer. Setting were as 
follows: excitation wavelength (410 nm) emissions wavelength (340 nm) slit width (5 
mm). The device plotted the intensity (a.u.) of NPN in real-time. After 100s or 50s 100 
µL of 20% glucose was added. When required, inhibitors PAβN or NMP were added 
200s after the addition of glucose. 40 uL of PAβN added for final concentration of 20 
µg/ml and 80 uL of NMP was added for final concentration of 40 µg/mL. Fluorescence 
intensity was recoded for an additional 100s.  
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TABLE 20 Bacteria cell strains 
 
Strain Characteristics Plasmids Reference or 
Source 
JM109 endA1, recA1, gyrA96, thi, 
hsdR17 (rk–, mk+), relA1, 
supE44, Δ( lac-proAB), [F´ 
traD36, proAB, laqIqZΔM15] 
None  
MC4100 F- araD139Δ(argF-
lac)U139rpsL150 relAl flbB5301 
ptsF25 deoC1 thi-l rbsR 
None  
 MC4100 Δara ΔacrAB scar  None  
Null MC4100 Δara ΔacrAB scar  pACYC184 Soparkar et al., 
2015 
Wildtype MC4100 Δara ΔacrAB scar  pACYC184 AcrAB Soparkar et al., 
2015 
B87-018 MC4100 Δara ΔacrAB scar  pACYC184 (AcrAWT AcrBF610A) Soparkar et al., 
2015 
B87-022 MC4100 Δara ΔacrAB scar  pACYC184 (AcrAWT AcrBY49F) This study 
B87-023 MC4100 Δara ΔacrAB scar pACYC184 (AcrAWT AcrBY49A) This study 
B87-024 MC4100 Δara ΔacrAB scar  pACYC184 (AcrAWT AcrBD153K) This study 
B87-025 MC4100 Δara ΔacrAB scar  pACYC184 (AcrAWT AcrBD153A) This study 
B87-027 MC4100 Δara ΔacrAB scar  pACYC184 (AcrAWT AcrBF610A+Y49F) This study 
B87-028 MC4100 Δara ΔacrAB scar  pACYC184 (AcrAWT AcrBF610A+Y49A) This study 
B87-029 MC4100 Δara ΔacrAB scar  pACYC184 (AcrAWT AcrBF610A+D153K) This study 
B87-030 MC4100 Δara ΔacrAB scar  pACYC184 (AcrAWT AcrBF610A+D153A) This study 
B87-032 
and B87-
050 
MC4100 Δara ΔacrAB scar  pACYC184 (AcrAWT AcrBF610A+Y49S) Soparkar et al., 
2015 
B87-033 MC4100 Δara ΔacrAB scar  pACYC184 (AcrAWT AcrBF610A+D153E) Soparkar et al., 
2015 
B87-034 
and B87-
067 
MC4100 Δara ΔacrAB scar  pACYC184 (AcrAWT AcrBD153E) This study 
B87-035 
and B87-68 
MC4100 Δara ΔacrAB scar  pACYC184 (AcrAWT AcrBG288C) Soparkar et al., 
2015 
B87-036 
and B87-
065 
MC4100 Δara ΔacrAB scar  pACYC184 (AcrAWT AcrBY49S) This study 
B87-037 
and B87-
066 
MC4100 Δara ΔacrAB scar  
 
pACYC184 (AcrAWT AcrBV127G) This study 
B87-039 MC4100 Δara ΔacrAB scar  pACYC184 (AcrAWT AcrBL486W) Soparkar et al., 
2015 
B87-052 MC4100 Δara ΔacrAB scar  pACYC184 (AcrAWT AcrBF610A+G288C) Soparkar et al., 
2015 
B87-049 MC4100 Δara ΔacrAB scar pACYC184 (AcrAWT AcrBF610A+L486W) Soparkar et al., 
2015 
B87-056 MC4100 Δara ΔacrAB scar  pACYC184 (AcrAWT 
AcrBF610A+V127G+L486W) 
This study 
B87-053 MC4100 Δara ΔacrAB scar  pACYC184 (AcrAWT 
AcrBF610A+D153E+L486W) 
This study 
B87-047 MC4100 Δara ΔacrAB scar  pACYC184 (AcrAWT 
AcrBF610A+G288C+L486W) 
This study 
B87-062 MC4100 Δara ΔacrAB scar  pACYC184 (AcrAWT AcrBG288C+L486W) This study 
B87-064 MC4100 Δara ΔacrAB scar  pACYC184 (AcrAWT AcrBV127G+L486W) This study 
B87-065 MC4100 Δara ΔacrAB scar  pACYC184 (AcrAWT AcrBD153E+L486W) This study 
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TABLE 21 Site-directed Mutagenesis primers 
 
Primer 
Name 
Gene Sequence (Forward primers) 
Y49A acrB 5’-CGATCTCCGCgTCCgcCCCCGGCGCTGATGCG-3’ 
Y49F acrB 5’-CGATCTCCGCgTCCTtCCCCGGCGCTGATGCG-3’ 
D153A acrB 5’-GCACCATGACGCAaGAGGcgATCTCCGACTACGTGG-3’ 
D153K acrB 5’-GGCACCATGACGCAaGAGaAaATCTCCGACTACGTGGCG-3’ 
L486W acrB 5’ CGGTACTGGTGGCGTgGATCCTGACTCCtGCTCTTTGTGCC-3’ 
A610F acrB 5’-CGTTGAGTCGGTGTTCGCgGTTAACGGCTTCGGC-3’ 
Note: Bolded underline nucleotides are the mutated residue while the non-bolded underline nucleotides are silent 
mutations made to maintain annealing temperatures and/or GC contents.  
 
 
TABLE 22 Site-Directed Mutagenesis cycling parameters 
 
(18 cycles) Temperature (ºC) 
Time 
(minutes:seconds) 
1 95 2:00 
2 95 :20 
3 60 :10 
4 68 4:30 
 
 
TABLE 23 Sequencing primers 
 
Primer name Gene  Sequence  
AcrB-F1 (sites 49, 127, 
153)  
acrB 5’-CCATTATCATCATGTTGGCAGG -3’ 
AcrB-F3 (site 288) acrB 5’- TCGAAGATTGAGCTGGGTGG -3’ 
AcrB-F4 (site 486)  acrB 5’- CCATCGGCCTGTTGGTGG -3’ 
AcrB-F5 (site 610) acrB 5’- GCACCACTACACCGACAGC -3’ 
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